INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
GA
Corporate insider

Grimaud Brett A.

SVP, GEN COUNSEL AND SECRETARYCIK 0001966698

EDGAR filingsOpen in network
Disclosed transactions7
Buys / sells0 / 0
Max Insider Score19
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
107.8K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Theravance Biopharma, Inc.SVP, GEN COUNSEL AND SECRETARY · Nov 24, 2025
9
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D
—
223.9K sh
Sep 23, 2026
Sep 24, 2026
traded Sep 23, 2026
+1d
SEC FORM 4

Evidence

9
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
23.4K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

12
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Tax withholding
F$135K
7,952 sh
Aug 20, 2026Aug 24, 2026
traded Aug 20, 2026
+4dSEC FORM 4

Evidence

12
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Tax withholding
F$146K
8,829 sh
May 20, 2026May 22, 2026
traded May 20, 2026
+2dSEC FORM 4

Evidence

19
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Tax withholding
F$410K
20.8K sh
Feb 20, 2026Feb 24, 2026
traded Feb 20, 2026
+4dSEC FORM 4

Evidence

19
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Tax withholding
F$341K
19.0K sh
Nov 20, 2025Nov 24, 2025
traded Nov 20, 2025
+4dSEC FORM 4

Evidence